Key facts
- Developer of therapies designed for the treatment of mental health conditions.
- It has raised $600K; the latest was Grant ($30K) in Feb 2026.
- Notable investors include Innovate UK, Creative Destruction Lab, University of Toronto, Development Bank of Wales, Welsh Government — 11 tracked in total.
- Status: Privately Held (backing).
Free account
See the evidence behind this price
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for MeOmics
- ·The full record, as it builds
Create free account
No card required
Funding rounds
No rounds on record
No funding rounds for MeOmics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Pro members can request priority coverage with a 48-hour turnaround.
About MeOmics
Developer of therapies designed for the treatment of mental health conditions. The company's platform uses physiological assays to measure biological readouts from interacting neurons derived from clinically and genetically characterised patient stem cell lines, enabling clinicians and researchers in mental healthcare to support personalised treatment decisions and improve care outcomes.
- Sector
- Healthcare
- HQ
- Cardiff, United Kingdom
- Founded
- 2020
- Employees
- 8
- Website
- meomics.tech/
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
MeOmics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.